- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We're Reading: Gene Editing Moratorium; e-Cigarette Sales; PBMs Invited to Drug Price Hearing
An international group of scientists has called for a global moratorium on gene-edited babies; proposed guidance would limit the sale of flavored e-cigarettes; and the Senate has invited executives from 5 pharmacy benefit managers (PBMs) to testify at a hearing on drug prices.
Scientists Call for Moratorium on Gene Editing
Proposal Would Limit Sales of Flavored e-Cigarettes
Senate Committee Invites Pharmacy Benefit Manager (PBM) Execs to Testify
Months after the controversial births of the world's first gene-edited babies, a group of 18 researchers from around the globe are calling for a world-wide moratorium on editing DNA in human sperm, eggs, and embryos, reported The Wall Street Journal. The researchers, who include some inventors of CRISPR, said that a moratorium would prevent irresponsible use of the technology before it causes irreversible changes.As part of the FDA’s ongoing effort to combat teen vaping, Commissioner Scott Gottlieb, MD, introduced proposed guidance that would limit the sale of flavored e-cigarettes to vape shops that bar sales to minors. The changes would not apply to menthol, mint, and tobacco flavors. According to The Hill, the proposal would likely ban sales of e-cigarettes at gas stations and convenience stores.The Senate Finance Committee has invited 5 executives from PBMs to its third drug pricing hearing on April 3. According to Reuters, Committee Chair Senator Chuck Grassley, R-Iowa, and Senator Ron Wyden, D-Oregon, invited executives from UnitedHealth Group’s OptumRx Cigna, Humana, CVS Caremark, and Prime Therapeutics to testify on rising prescription drug prices.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
